Spots Global Cancer Trial Database for Immune Persistence After the Whole Vaccination Shcedule With Recombination Quadrivalent HPV Vaccine
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Immune Persistence After the Whole Vaccination Shcedule With Recombination Quadrivalent HPV Vaccine
Official Title: Evaluating the Immune Persistence of Recombination Quadrivalent HPV Vaccine (Type 6, 11, 16, 18) in Healthy Chinese Female Subjects Aged 9 to 45 Years: A Phase 3, Open-label, Non-randomized Clinical Trial
Study ID: NCT05371353
Interventions
Study Description
Brief Summary: To access the immune persistence of Chinese women aged 9-45 years after receiving quadrivalent HPV vaccine with the immunization schedule of 0, 2 and 6 months.
Detailed Description:
Eligibility
Minimum Age: 9 Years
Eligible Ages: CHILD, ADULT
Sex: FEMALE
Healthy Volunteers: Yes
Locations
Yangchun Center For Disease Prevention And Control, Yangchun, Guangdong, China
Center for Disease Control and Prevention, Mianyang, Sichuan, China
Contact Details
Name: Jikai Zhang
Affiliation: Guangdong Center for Disease Prevention and Control
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
